Close Menu

Exact Sciences

Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.

The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.

Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.

Get the latest news from Invitae, Exact Sceicnes, Danaher, SkylineDx, Personalis, and Seegene for the week of 6/28/19.

Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.

During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.

Overall, the share prices for 18 of the index's 27 companies fell month over month. Exact Sciences was the only firm whose share price improved in the double digits.

The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.

The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.

The four-protein signature is associated with early forms of colon cancer that are most likely to progress into later stages of the disease.

Pages